Although RB was first identified as a tumour suppressor over 20 years ago, the implications of RB loss for tumour biology remain enigmatic. This Perspective discusses how context-specific consequences of RB inactivation might influence the response of a tumour to a range of therapeutic agents.
- Erik S. Knudsen
- Karen E. Knudsen
